SCHEMBL6835519

SCHEMBL6835519

COc1ccc(CNC(=O)c2ccc3c(c2)C(=O)C(Cc2ccc(F)c(Cl)c2)[S+]([O-])N3)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
MAPK1 P28482 1/20 0.44
MAPT P10636 6/20 0.43
LMNA P02545 1/20 0.43
POLB P06746 1/20 0.43
GAA P10253 1/20 0.43
KLKB1 P03952 1/20 0.41
DRD2 P14416 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
ROCK2 O75116 1/20 0.41
ROCK1 Q13464 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
TAS1R3 Q7RTX0 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
TAS1R2 Q8TE23 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6835368 0.94 ALDH1A1 (0.44) ALDH1A1MAPK1MAPTLMNAPOLB
SCHEMBL6835283 0.93 LMNA (0.47) ALDH1A1MAPK1MAPTLMNAPOLB
SCHEMBL6831844 0.93 ALDH1A1 (0.45) ALDH1A1MAPK1MAPTLMNAPOLB
SCHEMBL6831721 0.92 MAPT (0.47) ALDH1A1MAPK1MAPTLMNAPOLB
SCHEMBL6834773 0.91 MAPT (0.42) MAPTLMNAPOLBDRD2HSP90AA1
SCHEMBL6835304 0.89 ALDH1A1 (0.46) ALDH1A1MAPK1MAPTLMNAPOLB
SCHEMBL6837120 0.88 TP53 (0.47) ALDH1A1MAPK1MAPTLMNAPOLB
SCHEMBL6683279 0.87 NPC1 (0.49) ALDH1A1MAPK1MAPTLMNAPOLB
SCHEMBL6835367 0.85 EPHX2 (0.44) MAPTLMNAHSP90AA1HSP90AB1EPHX2
SCHEMBL6837223 0.84 PPARG (0.43) MAPTLMNAPOLBDRD2HSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors HICKS JAMES LESTER (US) 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors MMP13, MMP26, MMP9 ALDH1A1 1202/4885MAPK1 857/4885MAPT 2365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.